An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma
Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), O. Dereure(Beth Israel Deaconess Medical Center), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), A. Szenik(Centre Hospitalier Universitaire de Besançon), Célèste Lebbé(Inserm), Thierry Lesimple, G. Jeudy(CHU Dijon Bourgogne), L. Machet(Université de Tours), F. Aubin(Centre Hospitalier Universitaire de Besançon), Florent Grange(Hôpital Lyon Sud), Jean‐Jacques Grob(Aix-Marseille Université), A. Denden(Novartis (France)), Laurent Mortier, Caroline Robert(Institut Gustave Roussy), Brigitte Dréno(Nantes Université), Eve‐Marie Neidhardt(Centre Léon Bérard), C. Bédane(Central Michigan University)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k